Cite
The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals.
MLA
Annan, Naa Torshie, et al. “The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 2, June 2009, pp. 140–46. EBSCOhost, https://doi.org/10.1097/QAI.0b013e3181a56e81.
APA
Annan, N. T., Nelson, M., Mandalia, S., Bower, M., Gazzard, B. G., & Stebbing, J. (2009). The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 51(2), 140–146. https://doi.org/10.1097/QAI.0b013e3181a56e81
Chicago
Annan, Naa Torshie, Mark Nelson, Sundhiya Mandalia, Mark Bower, Brian G. Gazzard, and Justin Stebbing. 2009. “The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 51 (2): 140–46. doi:10.1097/QAI.0b013e3181a56e81.